Background:Laparoscopic cholecystectomy (LC) is the treatment of choice for symptomatic cholelithiasis substituting the conventional open method of cholecystectomy.Although post-operative pain is much less severe than that induced by open cholecystectomy, it is still not a pain-free procedure, which is why many patients refrain from early recovery, a major hurdle in enhanced recovery after surgery.This study was conducted to assess the efficacy of ropivacaine as post analgesic agent in patients undergoing laparoscopic cholecystectomy.Materials and Methods:This study comprised of 100 subjects undergoing laparoscopic cholecystectomy (LC). 2 doses of ropivacaine were used; 0.75% and 0.5%. 50 subjects were treated with 0.75% ropivacaine and had been assigned to Group 1 and the remaining 50 subjects had been treated using 0.5% ropivacaine. The efficacy of both the doses had been compared and the findings were tabulated. Statistical analysis was conducted using SPSS software.Results:The duration of surgery using 0.75% ropivacaine was 135.2±12 minutes and the duration of surgery using 0.5% ropivacaine was 129.7±9 minutes. The duration of stay in PACU with 0.75% ropivacaine and 0.5% ropivacaine was 163.5±64 minutes and 158.4±57 minutes, respectively. Blood loss with using 0.75% ropivacaine and 0.5% ropivacaine was 17.8 ± 6.0 ml and 21.9 ± 8.4 ml, respectively. Nausea was seen in 3 subjects of group 1 and 9 subjects of group 2. Vomiting was evident in 2 subjects of group 1 and 5 subjects of group 2. Pruritis was seen in 2 subjects of group 2 and respiratory depression was seen in only 1 patient of group 2.Conclusion:Intraperitoneal administration of ropivacaine before and after surgery significantly decreases postoperative pain. However; the duration of surgery and the duration of stay in PACU with 0.75% ropivacaine was longer compared to 0.5% ropivacaine. Side effects such as nausea, vomiting, pruritis and depression were seen commonly in subjects treated using 0.5% ropivacaine, while only a few side effects were observed among subjects treated with 0.75% ropivacaine.